

Supplemental Table 1. Baseline characteristics of patients with mucosal melanoma ($N = 33$).

Characteristic	Number of patients, %
Age, years	
Median	54.0
Range	27.0 - 70.0
Sex	
Male	13 (39.4)
Female	20 (60.6)
ECOG performance status	
0	20 (60.6)
1	13 (39.4)
Prior systemic chemotherapy	
None	31 (93.9)
First line	2 (6.1)
Location of primary lesion	
Nasal cavity	6 (18.2)
Oral cavity	5 (15.2)
Esophagus	7 (21.2)
Genital tract	7 (21.2)
Rectum	5 (15.2)
Unknown	2 (6.1)
Sinus	1 (3.1)
Stage at treatment	
III	7 (21.2)
IV, M1a	9 (27.3)
IV, M1b	11 (33.3)
IV, M1c	6 (18.2)
Prior systemic therapy	
Yes	2 (6.1)
No	31 (93.9)
LDH	
\leq ULN	24 (72.7)
$>$ ULN and $<$ $2 \times$ ULN	9 (27.3)
$>$ $2 \times$ ULN	0
Mutation Status	
<i>BRAF</i> *	1 (3.0)
<i>RAS</i>	9 (27.3)
<i>NF1</i>	4 (12.1)
<i>BRAF/RAS/NF1</i> triple wild type	20 (60.6)
<i>KIT</i>	6 (18.2)
PD-L1 Result†	
Positive	12 (36.4)
Negative	21 (64.6)

NOTE: Values are numbers and percentages unless otherwise noted.

Abbreviations: ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; PD-L1, programmed death ligand-1; ULN, upper limit of normal.

*BRAF mutant, n = 1 (V600E).

†Positive was defined as 1% or more of tissue cells expressing PD-L1 by SP263 immunohistochemistry staining.